Vosaroxin
- Generic Name
- Vosaroxin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N5O4S
- CAS Number
- 175414-77-4
- Unique Ingredient Identifier
- K6A90IIZ19
- Background
Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 183
- Registration Number
- NCT00408603
- Locations
- ๐บ๐ธ
Sharp Clinical Oncology Research, San Diego, California, United States
๐บ๐ธThe Harry and Jeanette Weinberg Institute at Franklin Square, Baltimore, Maryland, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT00298896
- Locations
- ๐บ๐ธ
University of California Davis, Sacramento, California, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
- Conditions
- Leukemia, Lymphocytic, AcuteMyelodysplastic SyndromesLeukemia, Myeloid, ChronicLeukemia, Nonlymphocytic, Acute
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT00246662
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
๐บ๐ธH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
- Conditions
- Neoplasms
- First Posted Date
- 2004-10-15
- Last Posted Date
- 2007-05-10
- Lead Sponsor
- Sunesis Pharmaceuticals
- Registration Number
- NCT00094159
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
- Conditions
- Neoplasms
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2007-05-10
- Lead Sponsor
- Sunesis Pharmaceuticals
- Registration Number
- NCT00091585
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.